SUNRISE, FL / CRWEPRESSRELEASE / August 27, 2015 / Bioheart, Inc. (OTCMKTS:BHRT)announces today its plans to change its name to U.S. Stem Cell, Inc. and that it has filed with the Securities and Exchange Commission a Preliminary Information Statement on Schedule 14C to commence the process to execute a 1,000 to 1 reverse stock split and change the name. The Company’s new brand identity will be:
Management believes that the reverse stock split will elevate the Company from its current “penny stock” position enabling institutional investors who are precluded from investing in companies below certain price per share ranges to potentially consider investing in U.S. Stem Cell, Inc. Further, the reverse stock split will bring the company’s issued and outstanding Common Stock shares into a more manageable volume. As the process requires regulatory review, applicable notification of FINRA, as well as additional standard requirements for this action, there are no assurances as to the time frame for enactment and no guarantee that this action will transpire.
“Our physician customers and patient clients already know of us as U.S. Stem Celland now our corporate identity will match our product and service offerings,” stated Mike Tomas, President and CEO of U.S. Stem Cell, Inc. (formerly known as Bioheart Inc) “This is a new and exciting era for our Company. The ‘heart’ symbol remains, which represents the people, science, and tradition of excellence and history of Bioheart. U.S. Stem Cell is who we are today, a provider of state of the art physician administered regenerative medicine and cell therapy treatments to people who are in need–and a developer of novel, diversified and highly effective stem cell therapies. We trust that elevating the Company out of the penny stock classification will open our mission and plan to new potential investors–including institutional investors. We hope our new brand identity and price per share trading level will project our commitment to progress and outstanding performance. We are excited about the future for U.S. Stem Cell, Inc. and hope you benefit and share in our enthusiasm.”
About U.S. Stem Cell, Inc.
U.S. Stem Cell, Inc (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.
Our business includes the development of proprietary cell therapy products as well as revenue generating physician and patient based regenerative medicine / cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. Management maintains that revenues and their associated cash in-flows generated from our businesses will, over time, provide funds to support our clinical development activities as they do today for our general business operations. We believe the combination of our own therapeutics pipeline combined with our revenue generating capabilities provides the Company with a unique opportunity for growth and a pathway to profitability.
US Stem Cell Training, (“SCT”), an operating division of Bioheart, Inc., is a content developer of regenerative medicine / cell therapy informational and training materials for physicians and patients. SCT also provides in-person and online training courses which are delivered through in-person presentations at SCT’s state of the art facilities and globally at university, hospital and physician’s office locations as well as through online webinars. Additionally, SCT provides hands-on clinical application training for physicians and health care professionals interested in providing regenerative medicine / cell therapy procedures.
Vetbiologics, (“VBI”), an operating division of Bioheart, Inc., is a veterinary regenerative medicine company committed to providing veterinarians with the ability to deliver the highest quality regenerative medicine therapies to dogs, cats and horses. VBI provides veterinarians with extensive regenerative medicine capabilities including the ability to isolate regenerative stem cells from a patient’s own adipose (fat) tissue directly on-site within their own clinic or stall-side. VBI regenerative medicine technologies are designed, implemented and produced according to the highest standards. VBI follows the FDA guidelines for human cellular therapy production which means each product produced must be validated and must pass stringent criteria.
US Stem Cell Clinic, LLC, (“SCC”), a partially owned investment of Bioheart, Inc., is a physician run regenerative medicine / cell therapy clinic providing cellular treatments for patients afflicted with neurological, autoimmune, orthopedic and degenerative diseases. SCC is operating in compliance with the FDA 1271s which allow for same day medical procedures to be considered the practice of medicine. We isolate stem cells from bone marrow and adipose tissue and also utilize platelet rich plasma.
Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “to,” “plan,” “expect,” “believe,” “anticipate,” “intend,” “could,” “would,” “estimate,” or “continue,” or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2014, and its Quarterly Reports on Form 10-Q.
13794 NW 4th Street, Suite 212
Sunrise, Florida 33325
SOURCE: Bioheart, Inc.